US$250m market share
First generic will get atleast 20-30% market share
Gross Profit margin ~55%
Overheads about 2% of revenue (using Teva portfolio metrics) - I use 4%
Simple math gets you a rough EBITDA impact. Can play with numbers to be more conservative.
- Forums
- ASX - By Stock
- MYX
- Ann: FDA approval and first generic launch of Acticlate tablets
MYX
mayne pharma group limited
Add to My Watchlist
0.19%
!
$5.20

Ann: FDA approval and first generic launch of Acticlate tablets, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.20 |
Change
-0.010(0.19%) |
Mkt cap ! $422.4M |
Open | High | Low | Value | Volume |
$5.22 | $5.25 | $5.07 | $964.0K | 186.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4000 | $5.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.20 | 2500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 158 | 5.070 |
1 | 100 | 5.060 |
2 | 10122 | 5.050 |
1 | 320 | 5.030 |
2 | 3600 | 5.020 |
Price($) | Vol. | No. |
---|---|---|
5.200 | 2500 | 1 |
5.230 | 600 | 1 |
5.240 | 10000 | 1 |
5.250 | 25244 | 2 |
5.260 | 500 | 1 |
Last trade - 16.10pm 23/07/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |